Active — Not RecruitingNot Applicable

Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial

United States300 participantsStarted 2020-12-20

Plain-language summary

BioBOOST is a multicenter, observational study of the effect of derangements in brain physiologic parameters on brain injury biomarker levels in patients with severe traumatic brain injury.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enrolled in BOOST-3 (this is an ancillary study to the BOOST-3 trial) * BOOST-3 participant is enrolled at a BioBOOST site * Able to maintain initial blood sample within 24 hours of injury * Provide proxy informed consent Exclusion Criteria: * Profoundly anemic (subjects who are profoundly anemic require blood transfusion) * Age less than 18 years

What they're measuring

Peak levels of glial fibrillary acidic protein (GFAP)

Timeframe: First 5 days after injury

Peak levels of ubiquitin C-terminal hydrolase L1 (UCH-L1)

Timeframe: First 5 days after injury

Peak levels of neurofilament light chain (NfL)

Timeframe: First 5 days after injury

Peak levels of Tau

Timeframe: First 5 days after injury

Trial details

NCT IDNCT04565119

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More TBI (Traumatic Brain Injury) trials